1 – 10 of 947
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2025
- A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer (2025) BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. 1880(1).
- Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer : a phase 2 trial : results of secondary endpoints (2025) EUROPEAN UROLOGY FOCUS.
- 3D perfusion models allow for more selective clamping during robot-assisted partial nephrectomy : a retrospective analysis (2025) EAU25 - 40th Annual EAU Congress, Abstracts.
- Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer (2025) European Urology Oncology. 8(1). p.111-118
- Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up (2025) CURRENT ONCOLOGY. 32(2).
- Variant genital gender-affirming surgery : a systematic review (2025) BJU INTERNATIONAL. 135(1). p.40-53
- A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer (2025) NPJ PRECISION ONCOLOGY. 9(1).
- Prostate-specific Membrane Antigen-targeted Radionuclide Therapy as Adjunct to Immune Checkpoint Inhibition in an Immunocompetent Murine Model for Oral Squamous Cell Carcinoma (2025) 11th European Congress on Head and Neck Oncology.
- Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial (2025) NATURE MEDICINE. 31(1).
- 2024
- Moderate hypofractionated radiotherapy for prostate cancer : 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial (2024) RADIOTHERAPY AND ONCOLOGY. 193.